NeuroPace Inc Breakfast Symposium draws strong interest in epilepsy treatment advances

NeuroPace Inc Breakfast Symposium draws strong interest in epilepsy treatment advances
NeuroPace Inc leads neuromodulation talks

NeuroPace Inc convened with leading epilepsy specialists at ASSFN2026, hosting a Breakfast Symposium on responsive thalamic neuromodulation for drug-resistant epilepsy.

The event featured experts Dr. John Rolston, Dr. Mark Richardson, and Dr. Martha Morrell, who discussed progress in neuromodulation technologies. The symposium attracted robust attendance, reflecting rising interest in innovative treatments within the epilepsy community.

NeuroPace previously presented early Nautilus study results and device feasibility for Lennox-Gastaut syndrome at an ASSFN breakfast symposium with top epilepsy clinicians. The company has also showcased its RNS System for drug-resistant focal epilepsy, inviting clinicians to visit its exhibit at the same conference to explore the device's use in adults with refractory seizures. These events reflect ongoing engagement with the clinical community at major neurosurgery meetings.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.